Announced Date: 2025-06-26 (June 26, 2025)
Asset Name: 9MW3811
Licensor: Mabwell (Shanghai) Bioscience (China)
Licensee (Buyer): Calico Life Sciences LLC (founded by Alphabet Inc)
.
Asset Modality: monoclonal antibody (mAb)
Asset Target: IL-11
Potential Indication: age-related diseases
Current Stage: Phase I trials in China and Australia
.
Scope of Authority:
Mabwell will grant Calico exclusive rights to develop, manufacture, and commercialize 9MW3811 in all regions except Greater China.
.
Payment Detail:
Mabwell will receive:
Upfront payment and potential near-term payments of up to $25 million,
Development, regulatory, and commercial milestones payment up to $571 billion.
Royalties on net sales.
.
Link:
.
Note:
Chinese Name of Mabwell (Shanghai) Bioscience 迈威生物（上海）
